(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 83.4MM | +24% |
Operating Income | 81K | -101% |
Operating Expenses | 83.3MM | - |
Net Income | 25.2MM | -282% |
R&D | 20.1MM | +17% |
G&A | 36.7MM | +7% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
The consensus price target hints at a 32.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals ( NASDAQ:KNSA ) Full Year 2023 Results Key Financial Results Revenue: US$270.3m (up 23% from FY...
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), a biopharmaceutical company focused on the discovery, acquisition, development, and commercialization of therapeutics for patients suffering from debilitating diseases with significant unmet medical need, has reported an insider sale according to a recent SEC filing.
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript February 28, 2024 Kiniksa Pharmaceuticals, Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Fourth Quarter and Full […]
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 136.36% and 15.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Anticipates Continued Expansion with ARCALYST and Advancements in Clinical Portfolio
– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint –– Abiprubart Phase 2 rheumatoid arthritis data from Cohort 4 and a new development indication expected in April 2024 –– Cash reserves of $206.4 million expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8: